Anti-aggregerende medicin: En potentiel kur mod Alzheimer's Disease? Anti-aggregating agents: A potential cure for Alzheimer's Disease?

Louise Julia Pigonska Hansen

Studenteropgave: Semesterprojekt

Abstrakt

Abstrakt Demens er et voksende problem, der dækker over hjernesygdomme hvor hukommelse og opførsel påvirkes. Hele 50-60 % af samtlige tilfælde demens skyldes Alzheimers (AD), en progressiv neurodegenerativ sygdom. Nuværende medikamenter til AD virker udelukkende dæmpende på symptomerne og påvirker ikke selve patogenesen. I dette projekt undersøges udviklingen af nye medikamenter der går ind og ændrer på patogenesen i AD. Projektet ser som litteraturstudie, på de anti-aggregerende medikamenter: Tramiprosate, PBT2 og Rember (Metylen Blå). Der sker først en indførelse i emnet, ved beskrivelse af patogenesen, med hovedvægt på de dele af der leder op til aggregering af proteiner. Protein misfolding beskrives også, da dette er den centrale del af aggregering af proteiner. De forskellige faser i udvikling af lægemidler beskrives kort, som indledning til en nærmere beskrivelse af de tre valgte anti-aggregerende medikamenter. Projektet diskuterer de beskrevne dele i patogenesen, for at underbygge de eksisterende hypoteser der er om rækkefølgende af disse. Ydermere diskuteres hvorvidt anti-aggregerende medikamenter har potentiale og om aggregering er et fornuftigt target at vælge i patogenesen for AD. Der konkluderes at aggregering af proteiner er et velvalgt target, idet forhindring eller formindskelse af dette vil forstyrre/afbryde udviklingen af AD. Dog mangler der stadig længere og flere kliniske forsøg i fase III med anti-aggregerende medikamenter, for med sikkerhed at kunne påvise en signifikant effekt af disse. Abstract Dementia is a growing issue, which concerns brain disorders affecting memory and cognition. Alzheimer’s Disease (AD), a neurodegenerative disease, is responsible for 50-60 % of the cases of dementia. The currently available agents for AD, only moderates the symptoms and does not affect the pathogenesis itself. This study will concern the development of new agents that affect the pathogenesis of AD. The study, as a literature study, views the anti-aggregating agents: Tramiprosate, PBT2 and Rember (Methylene Blue). First off the pathogenesis of AD is described, with emphasis on the parts leading to aggregation of proteins. Protein misfolding is also described, as it’s the main part of protein aggregation. The phases in development of new medicine are briefly described, leading to a closer view of the three chosen anti-aggregating agents. The study discusses the viewed parts of the pathogenesis, to support the existing hypothesis about the order of these. Furthermore it includes a discussion of potential of anti-aggregating agents and whether or not aggregation is a reasonably chosen target in the pathogenesis of AD. The study comes to the conclusion, that aggregation is a well-chosen target, as a reduction of this will disrupt the progression of AD. Yet the anti-aggregating agents still need multiple and longer period phase III clinical trials, to by certainty show a significant effect of these.

UddannelserBasis - Naturvidenskabelig Bacheloruddannelse, (Bachelor uddannelse) Basis
SprogDansk
Udgivelsesdato23 jun. 2010

Emneord

  • Aggregation
  • Protein misfolding
  • Alzheimer's Disease
  • PBT2
  • Tramiprosate
  • Alzheimer medicin
  • Anti-aggregerende
  • Methylene Blue
  • Tau
  • Rember
  • Amyloid
  • Alzheimer